Walking the Isobole of Drug Interaction (Walibi)

Walking the Isobole of Drug Interaction: Comparison of Hemodynamic Effects, Cerebral and Tissue Oxygenation for 4 Equipotent Combinations of Propofol and Remifentanil

The investigators study whether four equipotent combinations of propofol and remifentanil (as predicted by interaction models for "tolerance of laryngoscopy") result in identical haemodynamic conditions, independent of their relative different balance between the concentration of propofol and remifentanil.

Study Overview

• Status: Completed
• Conditions: Anesthesia; Hemodynamic Instability; Interaction; Disorder of Oxygen Transport
• Intervention / Treatment: Drug: Group A propofol + remifentanil; Drug: Group B propofol + remifentanil; Drug: Group C propofol + remifentanil; Drug: group D propofol + remifentanil

Detailed Description

In anesthesia, the synergistic interaction between hypnotics and opioids is applied daily to give adequate anesthesia and analgesia at significantly lower doses compared with the ones needed if only one drug was given to reach the same effect. A lot of research has been done to quantify these interactions with a focus on the desired effects (Tolerance of laryngoscopy, tolerance of shake and shout etc...), but the simultaneous interaction on the unwanted side effects is less well described. The response surface model of Bouillon et al. and other models predict combinations of propofol and remifentanil effect-site concentrations that lead to an equipotent desired effect. Due to the availability of the models, the anesthesiologists now could use the knowledge on interactions to target specific effects more accurately, using predefined equipotent combinations of drugs: for instance, a desirable 90% probability of tolerance of laryngoscopy (TOL90) in the population can be reached through either a high propofol/low remifentanil combination, but equally well through a low propofol-high remifentanil combination.

However, at this time it is not known whether some of the combinations of propofol and remifentanil have a favorable hemodynamic stability compared to other equipotent combinations. The researcher in this study want to determine whether equipotent combinations of remifentanil and propofol (all deliberately selected to evoke 90% probability of "tolerance to laryngoscopy"), result in different effects on the undesired side effects of anesthetics, such as hemodynamic instability (hypotension, changes in heart rate or cardiac output), decreases in cerebral or tissue oxygenation (both measured with near infrared spectroscopy).

• Study Type: Interventional
• Enrollment (Actual): 87
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Netherlands
  • Groningen, Netherlands, 9713EZ
    • University Medical Center Groningen

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Written informed consent
• General anesthesia required for the procedure
• Age: 18 years and older
• American Society of Anesthesiologists (ASA) physical status I to III

Exclusion Criteria:

• Refusal to participate in this study
• Contra-indications for the use of propofol or remifentanil
• BMI > 35 kg/m2
• Central nervous system disorders (i.e. cerebrovascular accident, dementia, seizures, psychiatric disorders)
• Relevant hepatic disease (Child B or higher)
• Regular use of medication that affects the central nervous system (i.e. benzodiazepines, antidepressants, antipsychotics, antiepileptic drugs)
• Use of alpha-agonists or beta-blockers
• Overt signs of alcohol abuse
• Use of preoperative benzodiazepines (on the day of the study)
• Beta blockers eye drips
• Overt signs of Drugs abuse

Study Plan

How is the study designed?

Design Details

• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Group A propofol + remifentanil; Propofol highest dose, remifentanil lowest dose, TOL 90% according to Bouillon model	Drug: Group A propofol + remifentanil; Predicted TOL90% according to Bouillon model; Other Names: propofol highest dose + remifentanil lowest dose
Active Comparator: Group B propofol + remifentanil; Propofol intermediate high, remifentanil intermediate low, TOL90% according to the Bouillon Model	Drug: Group B propofol + remifentanil; TOL 90% according to the Bouillon interaction model; Other Names: Propofol intermediate high+ remifentanil intermediate low
Active Comparator: Group C propofol + remifentanil; propofol intermediate low+ remifentanil intermediate high: TOL 90% according to the Bouillon interaction model	Drug: Group C propofol + remifentanil; TOL 90% according to the Bouillon interaction model; Other Names: propofol intermediate low+remifentanil intermediate high
Active Comparator: group D propofol + remifentanil; propofol lowest dose+ remifentanil highest dose: TOL 90% according to the Bouillon model	Drug: group D propofol + remifentanil; TOL 90% according to the Bouillon interaction model; Other Names: Propofol lowest dose+ remifentanil highest

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Blood pressure	Continuously stored on a laptop (systolic, diastolic and mean blood pressure over time) using a Philips Non Invasive Blood Pressure measurements every minute and a Nexfin monitor (continuous non invasive blood pressure measurement)	From start drug till intubation which will take on average 15 minutes of measurement

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Electro Encephalographic derived indices of anesthetic depth	Bispectral index, Wavelet Transformation (WAV) index, Quantium Consciousness Index (qCON), Quantium Nociception Index (qNOX) to observe whether multiple electroencephalographic derived depth of anesthesia indices indicate the same equipotent effect in all 4 groups. All these measures are unitless values that range between 100 (for a fully responsive condition) and 0 (for a fully unresponsive condition). All these measures are extracted from the same frontal electroencephalogram but use different composite mathematical algorithms to translate the cortical state in numbers. We want to observe whether these composite algorithms measure consistent behavior between groups. This outcome is mainly ment as hypothesis generating for future research.	From start first drug till intubation, which will take on average 15 minutes of measurement
Cerebral and tissue oxygenation	Continuously stored oxygenation saturation measured in tissue and cerebral cortex as measured by Near Infrared Spectrum Analysis (Forsyth monitor) and Inspectra monitor. Comparing differences between 4 groups with ANOVA.	From start drug till intubation, which will take on average 15 minutes of measurement
Heart rate	Difference in median/mean heart rate to determine differences between 4 groups with ANOVA.	From start first drug till intubation, which will take on average 15 minutes of measurement
Probability of tolerance to laryngoscopy	During pharmacological steady state of propofol/remifentanil, a laryngoscopy will be performed by one researcher and response or tolerance of the stimulus will be observed. A positive response will be defined as any somatic movement, swallowing or coughing during three minutes after laryngoscopy was applied. Also a increase in heart rate or systolic blood pressure of more than 20% from baseline values (one minute before laryngoscopy) will be defined as a positive response. Through PROBIT analysis we can plot the probability of response to laryngoscopy (%) as a function of respectively propofol or remifentanil drug concentrations.	one minute before laryngoscopy till three minutes after
Cardiac index	Non invasive estimation of Cardiac output and Cardiac index patterns through the Nexfin monitor. Determine the differences between groups through ANOVA.	From start first drug till intubation, which will take on average 15 minutes of measurement

Collaborators and Investigators

• Sponsor: University Medical Center Groningen
• Investigators: Principal Investigator: Hugo EM Vereecke, MD, PhD, University Hospital Medical center, university of groningen

Study record dates

Study Major Dates

• Study Start: February 1, 2014
• Primary Completion (Actual): September 1, 2015
• Study Completion (Actual): September 1, 2015

Study Registration Dates

• First Submitted: February 3, 2014
• First Submitted That Met QC Criteria: February 17, 2014
• First Posted (Estimate): February 20, 2014

Study Record Updates

• Last Update Posted (Estimate): December 4, 2015
• Last Update Submitted That Met QC Criteria: December 3, 2015
• Last Verified: December 1, 2015

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Anesthetics, Intravenous; Anesthetics, General; Anesthetics; Analgesics, Opioid; Narcotics; Hypnotics and Sedatives; Remifentanil; Propofol
• Other Study ID Numbers: WALIBI-001